Vijaya Diagnostic Centre Limited has informed the Exchange regarding a press release dated November 04, 2025, titled "Vijaya Diagnostic Centre Ltd announces Q2 & H1 FY26 results, with a 10.2% & 14.9% YoY revenue growth respectively".
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vijaya Diagnostic Centre announced its Q2 and H1 FY26 results, posting consolidated revenue of Rs. 2,015.6 million in Q2 (up 10.2% YoY) and Rs. 3,896.1 million in H1 (up 14.9% YoY), driven mainly by volume growth. EBITDA rose 7.7% YoY to Rs. 818.3 million in Q2, while profit after tax grew a more modest 2.7% to Rs. 432.8 million as margins came under pressure — EBITDA margin slipped 94 basis points to 40.6% and PAT margin fell 155 basis points to 21.5%. Operational metrics stayed healthy, with total tests up 8.3% YoY in Q2 and average realisation per footfall rising 4.3% to Rs. 1,685. On the expansion side, the company launched a new hub in Kolkata, received NCLT approval for the Medinova Diagnostic Services merger effective 1 April 2024, and signed a lease for a flagship centre in Bengaluru, reinforcing its network push across southern and eastern India.
Revenue growth is healthy, but the sharp Q2 margin compression (PAT up just 2.7% against revenue up 10.2%) may weigh on near-term sentiment, while continued network expansion and the Medinova merger add longer-term growth optionality for shareholders.